Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Smith & Nephew the Ultimate Retirement Share?

By Roland Head - Updated Apr 7, 2017 at 11:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Will shares in Smith & Nephew (LSE: SN) help you build a FTSE-beating retirement fund?

LONDON -- The last five years have been tough for those in retirement. Portfolio valuations have been hammered and annuity rates have plunged. There's no sign of things improving anytime soon, either, as the eurozone and the UK economy look set to muddle through at best for some years to come.

A great way of protecting yourself from the downturn, however, is by building your retirement fund with shares of large, well-run companies that should grow their earnings steadily over the coming decades. Over time, such investments ought to result in rising dividends and inflation-beating capital growth.

In this series, I'm tracking down the U.K. large caps that have the potential to beat the FTSE 100 over the long term and support a lower-risk income-generating retirement fund (you can see the companies I've covered so far on this page).

Today, I'm going to take a look at Smith & Nephew (LSE: SN.L) (NYSE: SNN), the maker of replacement joints, prosthetic limbs and other medical technology.

Smith & Nephew vs. FTSE 100
Let's start with a look at how Smith & Nephew has performed against the FTSE 100 over the last 10 years:

Total Returns 2007 2008 2009 2010 2011 10-year trailing average
Smith & Nephew 9.9% -23.3% 47.9% 7.3% -6.0% 6.7%
FTSE 100 7.4% -28.3% 27.3% 12.6% -2.2% 7.1%

Source: Morningstar. (Total return includes both changes to the share price and reinvested dividends. These two ingredients combined are what make it possible for equity portfolios to regularly outperform cash and bonds over the long term.)

The 10-year average trailing total return shows that Smith & Nephew has delivered shareholder returns broadly in-line with the FTSE 100 over the last decade, so could it be a retirement share?

What's the score?
To help me pinpoint suitable investments, I like to score companies on key financial metrics that highlight the characteristics I look for in a retirement share. Let's see how Smith & Nephew shapes up:

Item Value
Year founded 1856
Market cap 5.9 billion pounds
Net debt 88 million pounds
Dividend yield 1.7%
5-year average financials
Operating margin 21%
Interest cover 35x
EPS growth 16.6%
Dividend growth 12.9%
Dividend cover 4.8x

Sources: Morningstar, Digital Look, Smith & Nephew.

Here's how I've scored Smith & Nephew on each of these criteria:

Criteria Comment Score
Longevity 156 years, including 75 on the LSE. 5/5
Performance vs. FTSE It's kept pace with the index over the last decade. 3/5
Financial strength Attractive margins, and this year has seen growing net cash. 4/5
EPS growth Decent earnings growth, but this seems to be slowing. 3/5
Dividend growth Attractive growth, but with a yield that's well below average. 3/5
    Total: 18/25

Smith & Nephew is feeling the impact of global growth headwinds, but has streamlined its operations and has moved from a nominal net debt at the end of 2011 to report a 10% increase in trading profit and net cash of $379 million in its third-quarter results. However, this positive result doesn't disguise the company's lack of underlying growth -- something I think it may be too small to do without.

The reason for this is that despite being a FTSE 100 company, Smith & Nephew is far smaller than some of its U.S.-based peers and is periodically touted as a takeover or merger target. The company's core U.S. market is fairly flat, and it is focused on expanding in emerging markets, in which it delivered 6% underlying growth over the last quarter. However, emerging markets currently only account for 11% of the company's revenues -- whereas Europe, which accounts for 30% of revenues, poses "significant challenges," according to the company's most recent trading update.

On the positive side, Smith & Nephew has an unbroken history of dividend increases stretching back to at least 2000, the earliest year for which I could find data. Dividend growth is almost as important as dividend yield when creating a retirement portfolio, because of the need for your retirement income to keep pace with inflation. Despite this, Smith & Nephew's low payout ratio means that even if you bought the company's shares 10 years ago, your dividend yield on cost -- the current dividend payout divided by your original purchase price -- would only have risen to 3.9%. This is slightly above the FTSE 100 average of 3.3% but compares poorly to the 5.8% yield on cost currently being enjoyed by GlaxoSmithKline shareholders who bought their shares ten years ago.

Despite Smith & Nephew's attractions and its strong record of dividend growth, I think that there are better opportunities elsewhere for a retirement portfolio, one of which is pharmaceutical giant GlaxoSmithKline -- a company in which I own shares, as does one of the City's most successful income investors.

Top pharma income picks
GlaxoSmithKline is one of the eight biggest holdings of City legend Neil Woodford, whose dividend stock picks outperformed the wider index by a staggering 326% in the 15 years to June 2012. Woodford's record helps explain why he manages more private investors' money -- about 20 billion pounds, as of June 2012 -- than any other U.K. fund manager.

The good news is that you can learn about all eight of Neil Woodford's top holdings and how he generates such fantastic profits in this free Motley Fool report. Many of Woodford's choices look like excellent retirement shares to me and the report explains how he chose some of his biggest holdings.

This report is completely free and I strongly recommend you click here to download "8 Shares Held by Britain's Super Investor" today, as it is available for a limited time only.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Smith & Nephew plc Stock Quote
Smith & Nephew plc
SNN
$32.45 (-1.96%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.